Invokana is part of a new class of type 2 diabetes drugs known as sodium-glucose-cotransporter-2 (SGLT2) inhibitors. SGLT2 inhibitors are designed to control diabetes by blocking reabsorption of glucose by the kidneys, impacting normal kidney function and allowing more sugar to be passed from the body through urine. However, the FDA has recently issued a new warning for a number of SGLT2 inhibitors, including Invokana (canagliflozin). The agency has stated that these diabetes therapies can cause high levels of acid to build up in the blood, causing diabetic ketoacidosis, which can lead to diabetic coma or death.
In the FDA’s announcement, the agency warned patients using SGLT2 inhibitors that they should seek immediate medical attention if they experience any symptoms of ketoacidosis, including:
- Unusual fatigue or sleepiness
- Difficulty breathing
- Abdominal pain
Suthers & Harper is currently investigating claims on behalf of individuals who used Invokana or other SGLT2 inhibitors and suffered serious medical complications. Other SGLT2 inhibitors that have been associated with health complications include Glyxambi (empagliflozin/linagliptin), Farxiga (dapagliflozin), Xigduo XR (dapagliflozin/metformin), and Jardiance (empagliflozin).
If you or a loved one has experienced serious medical problems after using one of the products listed above, contact the experienced attorneys at Suthers & Harper. The firm has represented many victims injured by dangerous drugs and defective medical products. Such lawsuits are pursued under a contingency fee basis, meaning that there are no attorney fees unless a recovery is obtained. To discuss a potential lawsuit for yourself, a family member or friend, call 1-800-320-2384 or go to www.sutherslaw.com for a FREE consultation.